Cell type specific effects of TREM-2 on <i>S. pneumoniae</i> and TLR2 mediated cytokine production.

<p>(<b>A–B</b>) WT and <i>Trem-2</i><sup>−/−</sup> BMDM (n = 4 per genotype) were treated with 2×10<sup>7</sup> CFU/ml <i>S. pneumoniae</i> or 100 ng/ml LPS for 6 h and TNF-α (<b>A</b>) or KC (<b>B</b>) levels were measured in the supernatant. (<b>C–D</b>) WT and <i>Trem-2</i><sup>−/−</sup> AM (n = 4 per genotype/time point) were treated with 2×10<sup>7</sup> CFU/ml <i>S. pneumoniae</i> (<b>C</b>) or 10 µg/ml <i>S. pneumoniae</i> LTA (<b>D</b>) for the indicated times and KC and TNF-α levels were measured in the supernatant. (<b>E–F</b>) WT and <i>Trem-2</i><sup>−/−</sup> AM (n = 4 per genotype/MOI) were treated with the indicated doses of <i>S. pneumoniae</i> and TNF-α (<b>E</b>) and KC (<b>F</b>) levels were determined in the supernatant. Statistical comparisons are done versus WT cells (<b>A–B</b>) at a given timepoint (<b>C–D</b>), or at a particular MOI of <i>S. pneumoniae</i> (<b>E–F</b>), and indicated as: * p<0.05, ** p<0.005, *** p<0.001, **** p = <0.0001. All data represent mean ± SEM and are representative of two independent experiments.</p>